Our initial finding that reduced levels of MTA1 were inversely correlated with PTEN acetylation and activation, which resulted in significantly inhibited disease progression partly through the inhibition of p-AKT, revealed a novel deregulated signaling network in prostate cancer: the MTA1/PTEN/AKT pathway [10,11]. The gene discussed is AKT1; the disease is prostate carcinoma.